top of page
Multiple Myeoma Clinical Trials Currently Recruiting
2021 - (R) NCT04827563
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
2020 - (R) NCT04634552
Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
2020 - (R) NCT04394650
Phase 1 - CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in RRMM
2020 - (R) NCT04318327
Phase 1 - BCMA-directed CAR-T Cell Therapy in Adult Patients With RRMM
2020 - (R) NCT04244656
Phase 1 -A Safety and Efficacy Study Evaluating CTX120 Relapsed Refractory Myeloma
2019 - (R) NCT04184050
Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
2019 - (R) NCT04155749
Phase 1: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma
2019 - (R) NCT04133636
Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2016 - (R) NCT02899052
Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
2016 - (R) NCT02884102
MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
2016 - (R) NCT02675452
Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
2014 - (R) NCT02199665
Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)
2012 - (R) NCT01665794
Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NDMM
2021 - (R) NCT04923893
Phase 3 - Bort/Len/Dex f/b Cilta-cel f/b Len/Dex NDMM- ( No ASCT planned ) CARTITUDE-5
2019 - (R) NCT04108624
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
2019 - (R) NCT03989414
Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
2018 (R) NCT03500445
Phase 2: Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) NDMM
2018 - (R) NCT03729804
Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
2010 - (Active) NCT01208662
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
MGUS/SMM
bottom of page